Investor Relations

Overview

AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation.

read more

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

AnaptysBio Reports Imsidolimab POPLAR Phase 2 Clinical Trial in Moderate-to-Severe Palmoplantar Pustulosis (PPP) Did Not Meet Primary Endpoint

Imsidolimab treatment did not demonstrate statistically significant improvement over placebo in PPPASI change from baseline at week 16 primary endpoint Imsidolimab was generally well tolerated and no serious or severe adverse events were reported in the drug arm of the trial AnaptysBio does not

AnaptysBio Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Pipeline Updates

Positive topline data from GALLOP Phase 2 clinical trial of imsidolimab in moderate to severe generalized pustular psoriasis (GPP) announced in October 2020 , with Phase 3 trial initiation anticipated in mid-2021 Topline data from POPLAR Phase 2 imsidolimab clinical trial in palmoplantar pustulosis

GSK presents positive efficacy data of dostarlimab in mismatch repair-deficient (dMMR) solid cancers at ASCO Gastrointestinal Cancers Symposium -- Data from GARNET cohort F shows a 38.7% objective response rate with dostarlimab in patients with dMMR advanced solid cancers

GSK presents positive efficacy data of dostarlimab in mismatch repair-deficient (dMMR) solid cancers at ASCO Gastrointestinal Cancers Symposium -- Data from GARNET cohort F shows a 38.7% objective response rate with dostarlimab in patients with dMMR advanced solid cancers